Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Jack M. Berger, MS, MD, PhD and Nalini Vadivelu, MD
Guidelines for the use of controlled substances for the treatment of pain now consider inappropriate treatment, including undertreatment of pain, a departure from an acceptable standard of practice.
The open-access journal movement seeks to make medical research and treatment articles available free of charge to health professionals around the globe.
Health care policy changes are needed to minimize the risk to physicians responding to public health emergencies and aid in their longer-term responsibility of protecting and promoting the nation's health.
Two physicians argue that disaster preparedness for bioterrorist attacks diverts health care resources from other critical medical and public health needs.
The Model State Emergency Health Powers Act proposes state legislation that should be enacted to ensure an adequate and coordinated response to public health emergencies.
A centralized registry to provide information to consumers regarding the effectiveness of clinical trials is needed to help patients make informed decisions about treatment.